[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# Qiming Venture Partners

Qiming Venture Partners is making headlines for a significant HK$3 Million donation to the Tai Po Wang Fuk Court Aid Fund for post-fire recovery efforts. This philanthropic act highlights the firm's commitment to community support.

### About Qiming Venture Partners
Qiming Venture Partners is a venture capital firm that invests in technology and healthcare companies.  

### Engagements: X (24h)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:qiming-venture-partners/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/qiming-venture-partners/time-series/interactions.tsv)  
Current Value: X  
Daily Average: XXXXX  
X Week: XXX -XX%  
X Month: XXXXX -XXXX%  
X Months: XXXXXXX -XX%  
X Year: XXXXXXX +98%  
1-Year High: XXXXXX on 2025-01-26  
1-Year Low: X on 2025-12-08  

Engagements by network (24h):
X: X

  
  
### Mentions: X (24h)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:qiming-venture-partners/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/qiming-venture-partners/time-series/posts_active.tsv)  
Current Value: X  
Daily Average: XX  
X Week: XX -XX%  
X Month: XXX -XX%  
X Months: XXX -XX%  
X Year: XXXXX +24%  
1-Year High: XXX on 2025-07-15  
1-Year Low: X on 2025-12-01  

Mentions by network (24h):
X: X

  
  
### Creators: X (24h)
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:qiming-venture-partners/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/qiming-venture-partners/time-series/contributors_active.tsv)  
X unique social accounts have posts mentioning Qiming Venture Partners in the last XX hours which is no change from in the previous XX hours
Daily Average: X  
X Week: XX no change  
X Month: XX -XX%  
X Months: XX -X%  
X Year: XXX +22%  
1-Year High: XX on 2025-06-18  
1-Year Low: X on 2024-12-17  

The most influential creators that mention Qiming Venture Partners in the last XX hours

| Creator                                        | Rank | Followers | Posts | Engagements |
| -------                                        | ---- | --------- | ----- | ----------- |
| [@chuminhua432](/creator/twitter/chuminhua432) | X    | XXXXX     | X     | XX          |

[View More](/list/creators/qiming-venture-partners/100)
  
  
### Sentiment: XXX%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:qiming-venture-partners/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/qiming-venture-partners/time-series/sentiment.tsv)  
Current Value: XXX%  
Daily Average: XX%  
X Week: XXX% no change  
X Month: XXX% no change  
X Months: XXX% no change  
X Year: XXX% no change  
1-Year High: XXX% on 2024-12-14  
1-Year Low: XX% on 2025-08-26  

Most Supportive Themes:
- Portfolio Company Successes: (60%) Qiming Venture Partners' portfolio companies are achieving milestones and gaining recognition across various sectors, including biotech, robotics, and clean energy.
- Partnerships and Collaborations: (20%) Qiming Venture Partners' portfolio companies are actively forming strategic partnerships and collaborations to drive innovation and market expansion.
  
Most Critical Themes:
- Market Fluctuations: (10%) While specific market data is not provided, the overall engagement and mention trends suggest potential volatility or shifts in market interest related to Qiming Venture Partners and its portfolio.
  

### Top Qiming Venture Partners Social Posts
Top posts by engagements in the last XX hours

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"Cathay Capital has announced that it is leading Hundreds of millions of RMB Series A financing round for EMBIOS through its Sanofi-Cathay Healthcare Innovation Fund. EMBIOS has pioneered a key pipeline centered on the CXCR3 pathway. Its lead candidate YSC001 is designed around this pathway: on one hand it blocks the binding of CXCR3 to its ligands reducing the abnormal migration of immune cells to lesion sites; on the other it selectively eliminates these cells. EMBIOS submitted IND application for YSC001 last month. Sanofi Cathay Healthcare Innovation Fund:"  
[X Link](https://x.com/chuminhua432/status/1997887856321454405) [@chuminhua432](/creator/x/chuminhua432) 2025-12-08T04:35Z 3028 followers, 1673 engagements